4D Molecular Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €103.61M +375.2% -€309.69M -2.0% -298.9% +11 pp N/A N/A
    (estimated) €21.80M +503.3% -€315.92M +35.1% -1,448.9% +50 pp N/A N/A
    (estimated) €3.61M +11.7% -€233.80M +14.9% -6,469.1% -1.8 pp N/A N/A
    (estimated) €3.24M -5.3% -€203.55M +12.8% -6,289.4% -10 pp N/A N/A
    (estimated) €3.42M +10,656.8% -€180.48M +30.7% -5,282.4% +4.3K pp N/A N/A
    €31.76K -99.8% -€138.10M +59.5% -434,778.4% -4.3K pp -€112.28M +79.1% -353,510.8% -3.5K pp
    €17.79M +562.3% -€86.56M -0.2% -486.6% +27 pp -€62.68M -2.8% -352.4% +20 pp
    €2.69M -82.7% -€86.77M +48.0% -3,230.3% -29 pp -€64.51M +25.2% -2,401.7% -21 pp
    €15.48M +32.5% -€58.63M +20.8% -378.6% +0.37 pp -€51.53M +20.3% -332.8% +0.34 pp
    €11.69M +94.8% -€48.54M +6.8% -415.4% +3.4 pp -€42.84M +48.9% -366.7% +1.1 pp
    €6.00M -50.6% -€45.45M +454.3% -757.8% -6.9 pp -€28.76M +111.6% -479.6% -3.7 pp
    €12.13M +144.0% -€8.20M -14.9% -67.6% +1.3 pp -€13.60M -279.8% -112.1% -2.6 pp
    €4.97M -€9.63M -193.8% €7.56M 152.2%

    Notifications